Skip to main content
Premium Trial:

Request an Annual Quote

Magellan, Bruker Combining Technologies for Microbial Identification

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Magellan Biosciences today announced a deal with Bruker combining their technologies for microbial identification.

Under the terms of the deal, Magellan will develop and test an integrated cross-platform software interface for microbial identification gathered on Bruker's MALDI Biotyper mass spectrometer-based platform combined with results from Magellan's Trek-brand Sensititre susceptibility-testing platform.

Magellan will market and sell the products developed from the deal, the Chelmsford, Mass.-based company said, adding that the products are expected to improve the microbiology laboratory workflow for clinical, research, and veterinary customers.

Magellan did not disclose financial or other terms of the deal.

The MALDI Biotyper has been available in Europe with an IVD-CE mark and is labeled for research-use-only in the US. Bruker plans to seek approval from the US Food and Drug Administration and with regulators in Australia and Canada for the platform.

As a result of the partnership, the MALDI Biotyper's ability to rapidly identify more than 2,000 species of bacteria, yeast and fungi, along with Sensititre's capabilities will create "an expansive list of antimicrobial drugs and dilution ranges, enabling physicians to make more precise dosing decisions," Magellan President and CEO Hiroshi Uchida said in a statement.

Earlier this week, Magellan announced a deal with Miacom Diagnostics to bring that firm's molecular tests to the US and Canada.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.